Page 2 - Dr Reddy's Laboratories Limited

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Stocks to Watch today, Sept 23: Adani Power, KEC Int, JBM Auto, Vedanta

Stocks to Watch today, September 23, 2025: JBM Auto, Vedanta, JK Lakshmi, Dr Reddy's Labs and other stocks will be in focus

Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations

Dr Reddy's shares fell on Monday after the USFDA issued a Form 483 with five observations at its Hyderabad plant inspection

Dr Reddy's Q4 result: Net profit rises 22% to ₹1,594 cr, dividend declared

Dr Reddy's Q4 FY25 result: The board of directors have recommended a final dividend of ₹8 per share

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Nifty Pharma jumps 5% as US exempts reciprocal tariff on pharma goods

All 20 Nifty Pharma constituents settled in the green. Among others, Ipca Laboratories was up 4.59 per cent, Lupin was up 4.19 per cent, Cipla was up 3.28 per cent, Sun Pharma was up 3.41 per cent

Delhivery, Tata Elxsi: Trading strategies in stocks that hit 52-week lows

A total of 195 stocks hit fresh 52-week lows in intra-day trades on the BSE; off which among the top 500 shares Delhivery and Emcure Pharmaceuticals hit new all-time lows on Wednesday.

Maruti, Titan: View on stocks that may be impacted by US reciprocal tariffs

The US President Donald Trump has vowed to impose reciprocal tariffs on India and other countries from April 2, 2025 onwards. Here's a technical outlook on Indian stocks that may be impacted.

Infosys, ICICI Bank: 5 largecap stock ideas to trade amid market pullback

Technical charts show that shares of Infosys, ICICI Bank, Dr. Reddy's, Eicher Motors and Shriram Finance can potentially rally up to 15% from here on as Nifty attempts a pullback towards its 100-DMA.

Dr Reddy's faces Revlimid cliff, analysts split on future growth prospects

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance

Dr Reddy's Lab Q3 results: Profit up 2.5% at Rs 1,413 cr, revenue rises 16%

Dr Reddy's Lab Q3 results: Shares of Dr Reddy's closed at Rs 1,289.35 on Thursday ahead of its results

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Stocks to Watch, Jan 8, 2025: Tata Steel, Sobha, M&M, REC, SBI, RVNL, CESC

Stocks to Watch, Jan 8, 2025: From Tata Steel to Dr. Reddy's Labs, here is a list of stocks that will remain in focus today

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Kazakhstan authority imposes penalty of Rs 28.7 lakh on Dr Reddy's unit

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary. The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing. The order levies a penalty of KZT 17,597,212 (Rs 2.87 million), it added. "Based on our evaluation, there is no material impact on the financials, operations, or other activities of the company," the Hyderabad-based drug firm said.

Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab

Stocks to watch, Nov 21: Adani Group stocks, Cipla, UPL, BoB, Tata Tech

Here is a list of stocks that will be in focus from Adani Group stocks to Tata Power